Drug Details
| General Information of the Drug (ID: DR0619) | ||||
|---|---|---|---|---|
| Name |
Paricalcitol
|
|||
| Synonyms |
Paricalcitol; 131918-61-1; Zemplar; 19-Nor-1alpha,25-dihydroxyvitamin D2; Compound 49510; UNII-6702D36OG5; Compound-49510; CHEBI:7931; 6702D36OG5; (1R,3R)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5S)-6-hydroxy-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]cyclohexane-1,3-diol; (1R,3R,7E)-17beta-[(2R,3E,5S)-6-hydroxy-5,6-dimethylhept-3-en-2-yl]-9,10-secoestra-5,7-diene-1,3-diol; NCGC00182706-01; Paracalcin; 19-Nor-1,25-(OH)2D2; Zemplar (TN); 19-Nor-1-alpha,25-dihydroxyvitamin D2; HSDB 7360; Paricalcitol [USAN:USP:INN]; ABT-358; (7E,22E)-19-Nor-9,10-secoergosta-5,7,22-triene-1alpha,3beta,25-triol; Paricalcitol solution; PubChem18825; (1alpha.3beta,7E,22E)-19-Nor-9,10-secoergosta-5,7,22-triene-1,3,25-triol; SCHEMBL3655; DSSTox_CID_28566; DSSTox_RID_82838; DSSTox_GSID_48640; BIDD:GT0330; Paricalcitol (JAN/USP/INN); GTPL2791; CHEMBL1200622; DTXSID4048640; AMY2878; BDBM233195; (1R,3R)-5-{2-[(1R,3aS,4E,7aR)-1-[(2R,3E,5S)-6-hydroxy-5,6-dimethylhept-3-en-2-yl]-7a-methyl-octahydro-1H-inden-4-ylidene]ethylidene}cyclohexane-1,3-diol; ACT07192; EX-A4434; 19-Nor-1,25-dihydroxyvitamin D2; Tox21_112987; LMST04030163; s6681; ZINC13911941; AKOS005145562; AC-1198; BCP9001050; CS-0705; DB00910; 19-Nor-9,10-secoergosta-5,7,22-triene-1,3,25-triol, (1alpha,3beta,7E,22E)-; HY-50919; CAS-131918-61-1; C08127; D00930; W-5365; 918P611; Q155746; (1R,3R,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-octahydro-1-[(1R,2E,4S)-5-hydroxy-1,4,5-trimethyl-2-hexen-1-yl]-7a-methyl-4H-inden-4-ylidene]ethylidene]-1,3-cyclohexanediol; 1,3-Cyclohexanediol, 5-[(2E)-2-[(1R,3aS,7aR)-octahydro-1-[(1R,2E,4S)-5-hydroxy-1,4,5-trimethyl-2-hexen-1-yl]-7a-methyl-4H-inden-4-ylidene]ethylidene]-, (1R,3R,5Z)-
Click to Show/Hide
|
|||
| Molecular Type |
Small molecule
|
|||
| Disease | Hyper-parathyroidism [ICD-11: 5A51] | Approved | [1] | |
| Structure |
|
Click to Download Mol2D MOL |
||
| Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | ||||
| Formula |
C27H44O3
|
|||
| PubChem CID | ||||
| Canonical SMILES |
CC(C=CC(C)C(C)(C)O)C1CCC2C1(CCCC2=CC=C3CC(CC(C3)O)O)C
|
|||
| InChI |
1S/C27H44O3/c1-18(8-9-19(2)26(3,4)30)24-12-13-25-21(7-6-14-27(24,25)5)11-10-20-15-22(28)17-23(29)16-20/h8-11,18-19,22-25,28-30H,6-7,12-17H2,1-5H3/b9-8+,21-11+/t18-,19+,22-,23-,24-,25+,27-/m1/s1
|
|||
| InChIKey |
BPKAHTKRCLCHEA-UBFJEZKGSA-N
|
|||
| CAS Number |
CAS 131918-61-1
|
|||
| ChEBI ID | ||||
| TTD Drug ID | ||||
| DrugBank ID | ||||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug | ||||||
| Trandolapril | Homo sapiens | Click to Show/Hide the Molecular Data of This NP | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [2] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Expression | CCL5 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | COL1A1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | COL3A1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | FN1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | REN | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | SNAI1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | TNF | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | VIM | Molecule Info |
Pathway MAP
|
||
| Experimental
Result(s) |
Combination therapy had additive efficacy in retarding renal scar formation during obstructive nephropathy. | |||||
| Tretinoin | Homo sapiens | Click to Show/Hide the Molecular Data of This NP | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [2] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Expression | SNAI1 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | VIM | Molecule Info |
Pathway MAP
|
||
| In-vivo Model | The animal model was established by unilateral ureteral obstruction (UUO) in male CD-1 mice. | |||||
| Experimental
Result(s) |
Combination therapy of paricalcitol and trandolapril had additive efficacy in retarding renal scar formation during obstructive nephropathy. | |||||
| Target and Pathway | ||||
|---|---|---|---|---|
| Target(s) | Vitamin D3 receptor (VDR) | Molecule Info | [3] | |
| KEGG Pathway | Endocrine and other factor-regulated calcium reabsorption | Click to Show/Hide | ||
| 2 | Mineral absorption | |||
| 3 | Tuberculosis | |||
| NetPath Pathway | IL4 Signaling Pathway | Click to Show/Hide | ||
| Panther Pathway | Vitamin D metabolism and pathway | Click to Show/Hide | ||
| Pathway Interaction Database | Regulation of nuclear SMAD2/3 signaling | Click to Show/Hide | ||
| 2 | Direct p53 effectors | |||
| 3 | RXR and RAR heterodimerization with other nuclear receptor | |||
| 4 | Retinoic acid receptors-mediated signaling | |||
| 5 | Validated transcriptional targets of deltaNp63 isoforms | |||
| 6 | Validated transcriptional targets of TAp63 isoforms | |||
| Reactome | Nuclear Receptor transcription pathway | Click to Show/Hide | ||
| WikiPathways | Ovarian Infertility Genes | Click to Show/Hide | ||
| 2 | Nuclear Receptors in Lipid Metabolism and Toxicity | |||
| 3 | Nuclear Receptors Meta-Pathway | |||
| 4 | Vitamin D Receptor Pathway | |||
| 5 | Drug Induction of Bile Acid Pathway | |||
| 6 | Nuclear Receptors | |||
| 7 | Vitamin D Metabolism | |||
